<DOC>
	<DOCNO>NCT02791555</DOCNO>
	<brief_summary>The investigator evaluate effect Pradaxa comparison warfarin bone turnover bone density men woman atrial fibrillation .</brief_summary>
	<brief_title>Effect Pradaxa v Warfarin Bone Mass Bone Turnover Markers</brief_title>
	<detailed_description>1.0 Hypothesis : The direct thrombin inhibitor Pradaxa positively affect bone turnover marker increase bone mineral density woman men risk osteoporosis . 2.0 Goal : The goal study establish direct thrombin inhibitor Pradaxa positively affect bone turnover marker increase bone mineral density woman men risk osteoporosis . 3.0 Specific Aims . 3.1 To determine effect Pradaxa bone mineral density patient 6 12 month daily use . 3.2 To determine effect direct thrombin inhibitor Pradaxa bone turnover marker osteoclastic resorption ( measure serum level C-terminal peptide , N-telopeptide ) osteoblastic formation ( measure serum level bone-specific alkaline phosphatase , osteocalcin P1NP ) subject 6 12 month daily use . 3.3 To evaluate correlation among hemoclot , thrombin inhibitor test , change marker bone turnover change bone mineral density patient Pradaxa . 3.4 To determine effect Pradaxa change serum level receptor activator NF B-ligand ( RANKL ) , osteoprotegerin ( OPG ) , RANKL/OPG ratio , inflammatory marker ( IL-1b , IL-6 , TNF-alpha FGF-23 ) inhibitor Wnt/beta-catenin signal pathway include sclerostin DKK1 baseline , 6 12 month , understand mechanism effect Pradaxa bone . 4.0 Study design procedure . 4.1 Study Design : This prospective , Phase IV age-matched cohort study men woman start long-term treatment Pradaxa nonvalvular atrial fibrillation . This proof concept study evaluate effect Pradaxa , direct thrombin inhibitor bone density bone turnover marker comparison warfarin . 4.2 Subject Population : The investigator recruit patient nonvalvular atrial fibrillation prescribe Pradaxa cardiologist primary care provider long-term anticoagulant treatment participation study . The patient take Pradaxa study group , compare age-matched cohort men woman nonvalvular atrial fibrillation start long-term warfarin cardiologist primary care provider ( control group ) . The investigator evaluate 20 men 20 woman Pradaxa cohort another age-matched 20 men 20 woman warfarin cohort ( Pradaxa cohort : N = 40 , 20 men , 20 woman ; Warfarin cohort : N = 40 , 20 men , 20 woman ) . The two group determine base treatment assigned cardiologist primary care provider . As age influence risk osteoporosis , warfarin group age-matched Pradaxa group optimal comparison . This achieved offering participation patient take warfarin similar age patient recruit Pradaxa group . As woman likely develop osteoporosis effect Pradaxa may gender-based result difference level sex hormone , investigator evaluate cohort men woman pilot study comparison . The investigator expect see old cohort subject atrial fibrillation , also likely increase risk osteoporosis .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Age 50 , male female start Pradaxa Warfarin nonvalvular atrial fibrillation 2 . Able ambulate independently travel UConn Health Farmington CT 1 . Prior known history osteoporosis 2 . Chronic kidney disease creatinine clearance less 30 3 . Serum 25 hydroxyvitamin D level less 10 4 . Ongoing treatment medication interfere bone metabolism steroid , bisphosonates , denosumab , estrogen , SERMS 5 . Hypercalcemia , history Paget 's disease , history multiple myeloma , history monoclonal gammopathy uncertain significance</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pradaxa</keyword>
	<keyword>warfarin</keyword>
</DOC>